Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention

PREtreatment of Cilostazol Loading in Elective Percutaneous Coronary Intervention to Decrease Adverse Events

The purpose of this study is to investigate the effect of cilostazol loading before planned PCI on major adverse cardiac and cerebrovascular events in patients with coronary artery disease.

Inclusion Criteria:

• Patients undergoing elective PCI
• Presence of coronary lesions amenable to stent

Exclusion Criteria:

• Cardiogenic shock
• Urgent PCI
• Hypersensitivity to aspirin, clopidogrel, or cilostazol
• LVEF < 30% or congestive heart failure
• Bleeding diathesis
• leukocyte count < 3,000/mm3 and/or platelet count < 100,000/mm3
• aspartate aminotransferase or alanine aminotransferase > 3 times upper normal; serum creatinine > 2.0 mg/dl
• noncardiac disease with a life expectancy < 1 year
• inability to follow the protocol